CPT code 16022 covers the chemical destruction of benign skin lesions, up to and including 20 lesions, commonly used in outpatient dermatology and primary care offices. Nationally, this code is routine for the treatment of common cutaneous lesions such as warts and molluscum, and it informs billing, clinical documentation, and coverage discussions across major payers. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of clinical context for the procedure, the expected site-of-service settings, and the elements that influence coding and coverage decisions. The publication summarizes typical utilization patterns, common reimbursement considerations, and how benchmarks are reported for this service line. It also highlights any recent policy updates that affect billing practice and documentation expectations. The content is designed to assist coding professionals, billing managers, and clinical leaders in understanding where CPT code 16022 fits within outpatient dermatologic care and payer coverage frameworks.

Data not available in the input for specific modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and payer-specific rates.